Close
Novotech
Jabsco PureFlo 21 Single Use

QPSI Announces Acquisition Of Pharmaceutical Packaging Company, International Labs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Quality Packaging Specialists International, LLC (QPSI) has acquired 100% ownership of International Labs, LLC (INL) in an equity exchange transaction.

Terms of the transaction were not disclosed. INL, based in St. Petersburg, FL, delivers adherence packaging solutions for pharmaceutical products primarily to national retailers. INL has capacity to produce over 140 million units per year.  

“As an industry leader in contract packaging and supply chain management, this acquisition will build out QPSI’s product and service offerings, technical capabilities, and complement our commitment to serving customers with expansive, integrated network solutions focused on cost savings, accelerated speed to market and product innovations,” said Maurice Phelan, VP Pharmaceutical Operations. “This transaction will deliver significant and immediate value to our customers by offering increased primary packaging capabilities and direct-to-retail distribution. This allows us to continue providing our customers a dynamic approach to a complex and constantly evolving marketplace.”

About QPSI
QPSI, a certified minority business enterprise, is one of the largest privately owned, outsourced packaging supply chain solution providers in the US. It serves primarily Fortune 500 brands in the pharmaceutical, health, beauty and consumer goods sectors. With over 3 million square feet of capacity in 11 locations in the United States, QPSI manages and delivers to its customers innovative and high ROI solutions from package design to retail distribution. http://www.qpsiusa.com

 

 

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »